Han Fang, Zhang Yang, Shao Mingxia, Mu Qingjie, Jiao Xiaotong, Hou Ningning, Sun Xiaodong
Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Department of Endocrinology, Affiliated Hospital of Weifang Medical University, Weifang, China.
Clin Exp Pharmacol Physiol. 2018 Jan;45(1):50-57. doi: 10.1111/1440-1681.12851. Epub 2017 Oct 25.
The anti-contractile property of perivascular adipose tissue (PVAT) is abolished through an endothelium-dependent pathway in obesity. C1q/tumor necrosis factor-related protein (CTRP)9 improved endothelial function by promoting endothelium-dependent vasodilatation. The aims of this study were to investigate whether CTRP9 improves the anti-contractile effect of PVAT and protects against PVAT dysfunction in obese mice. The mice were treated with a high-fat diet with or without CTRP9 treatment. Thoracic aortas with or without PVAT (PVAT+ or PVAT-) were prepared, and concentration-dependent responses to phenylephrine were measured. Obese mice showed a significantly increased contractile response, which was suppressed by CTRP9 treatment both with and without PVAT. PVAT significantly reduced the anti-contractile effect in obese mice, which was partially restored by CTRP9 treatment. Treatment of the aortic rings (PVAT+) with inhibitors of AMP protein kinase (AMPK), Akt and endothelial nitric oxide synthase (eNOS) attenuated the beneficial effect of CTRP9 on PVAT. Similar results were observed when we pretreated the aortic rings with CTRP9 ex vivo. CTRP9 significantly enhanced the phosphorylation levels of AMPK, Akt and eNOS, and reduced superoxide production and TNF-α levels in PVAT from obese mice. Our study suggests that CTRP9 enhanced the anti-contractile effect of PVAT and improved PVAT function by activating the AMPK-eNOS pathway in obese mice.
在肥胖状态下,血管周围脂肪组织(PVAT)的抗收缩特性通过内皮依赖性途径被消除。C1q/肿瘤坏死因子相关蛋白(CTRP)9通过促进内皮依赖性血管舒张改善内皮功能。本研究的目的是探讨CTRP9是否能改善PVAT的抗收缩作用,并预防肥胖小鼠的PVAT功能障碍。小鼠接受高脂饮食,部分小鼠接受CTRP9治疗。制备带有或不带有PVAT的胸主动脉(PVAT+或PVAT-),并测量对去氧肾上腺素的浓度依赖性反应。肥胖小鼠的收缩反应显著增加,CTRP9治疗无论有无PVAT均能抑制该反应。PVAT显著降低了肥胖小鼠的抗收缩作用,CTRP9治疗可部分恢复该作用。用AMP蛋白激酶(AMPK)、Akt和内皮型一氧化氮合酶(eNOS)抑制剂处理主动脉环(PVAT+)减弱了CTRP9对PVAT的有益作用。当我们在体外对主动脉环进行CTRP9预处理时,观察到了类似的结果。CTRP9显著提高了肥胖小鼠PVAT中AMPK、Akt和eNOS的磷酸化水平,并降低了超氧化物生成和TNF-α水平。我们的研究表明,CTRP9通过激活肥胖小鼠的AMPK-eNOS途径增强了PVAT的抗收缩作用并改善了PVAT功能。